Another phase II, multicenter, open-label study in patients with unresectable stage IIIB/IV melanoma, evaluated whether baseline or changes in intratumoral CD8+ T-cell density were correlated with the T-VEC clinical response [46]. This evidence concerns the gene CD8A and melanoma.